Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth
Update your Virtual Booth on PharmaCompass, ask us 
About
euroPLX 90 LisboneuroPLX 90 Lisbon
Not Confirmed
Not Confirmed
02-03 March, 2026
BIO CEO & InvestorBIO CEO & Investor
Not Confirmed
Not Confirmed
02-03 March, 2026
Clinical OutsourcingClinical Outsourcing
Not Confirmed
Not Confirmed
03-04 March, 2026
List your booth number for exhibitions, ask us 
CONTACT DETAILS
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Events
Webinars & Exhibitions
euroPLX 90 Lisbon
Not Confirmed
Contact SuppliereuroPLX 90 Lisbon
euroPLX 90 LisboneuroPLX 90 Lisbon
Industry Trade Show
Not Confirmed
02-03 March, 2026
BIO CEO & InvestorBIO CEO & Investor
Industry Trade Show
Not Confirmed
02-03 March, 2026
Clinical OutsourcingClinical Outsourcing
Industry Trade Show
Not Confirmed
03-04 March, 2026
Drugs in Development
Details:
Mitoxantrone HCl is a small molecule drug candidate, which is currently being evaluated in Phase I/ Phase II clinical studies for the treatment of Lymphoma, T-Cell, Peripheral.
Lead Product(s): Mitoxantrone
Therapeutic Area: Oncology Brand Name: Undisclosed
Study Phase: Phase I/ Phase IIProduct Type: Cytotoxic Drug
Recipient: Sun Yet-Sen University Cancer Center
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable December 17, 2025
Lead Product(s) : Mitoxantrone
Therapeutic Area : Oncology
Highest Development Status : Phase I/ Phase II
Recipient : Sun Yet-Sen University Cancer Center
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Mitoxantrone HCl is a small molecule drug candidate, which is currently being evaluated in Phase I/ Phase II clinical studies for the treatment of Lymphoma, T-Cell, Peripheral.
Product Name : Undisclosed
Product Type : Cytotoxic Drug
Upfront Cash : Inapplicable
December 17, 2025
Details:
Amphotericin B Cholesteryl Sulfate Complex is a small molecule drug candidate, which is currently being evaluated in Phase III clinical studies for the treatment of Mycoses.
Lead Product(s): Amphotericin B cholesteryl sulfate
Therapeutic Area: Infections and Infectious Diseases Brand Name: Undisclosed
Study Phase: Phase IIIProduct Type: Miscellaneous
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable November 20, 2025
Lead Product(s) : Amphotericin B cholesteryl sulfate
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
A Study to Evaluate the Safety, Efficacy, and PPK of ABCD in Patients With IMD
Details : Amphotericin B Cholesteryl Sulfate Complex is a small molecule drug candidate, which is currently being evaluated in Phase III clinical studies for the treatment of Mycoses.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
November 20, 2025
Details:
Prusogliptin is a Other Small Molecule drug candidate, which is currently being evaluated in Phase III clinical studies for the treatment of Diabetes Mellitus, Type 2.
Lead Product(s): Prusogliptin,Dapagliflozin,Metformin
Therapeutic Area: Endocrinology Brand Name: Undisclosed
Study Phase: Phase IIIProduct Type: Miscellaneous
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable June 18, 2025
Lead Product(s) : Prusogliptin,Dapagliflozin,Metformin
Therapeutic Area : Endocrinology
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Prusogliptin + Dapagliflozin + Metformin Safety and Efficacy In T2DM
Details : Prusogliptin is a Other Small Molecule drug candidate, which is currently being evaluated in Phase III clinical studies for the treatment of Diabetes Mellitus, Type 2.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
June 18, 2025
Details:
Irinotecan HCl is a Other Small Molecule drug candidate, which is currently being evaluated in Phase IV clinical studies for the treatment of Neuroendocrine Tumors.
Lead Product(s): Irinotecan Hydrochloride,Fluorouracil,Calcium Folinate
Therapeutic Area: Oncology Brand Name: Undisclosed
Study Phase: Phase IVProduct Type: Miscellaneous
Recipient: Beijing GoBroad Hospital
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable June 11, 2025
Lead Product(s) : Irinotecan Hydrochloride,Fluorouracil,Calcium Folinate
Therapeutic Area : Oncology
Highest Development Status : Phase IV
Recipient : Beijing GoBroad Hospital
Deal Size : Inapplicable
Deal Type : Inapplicable
A Irinotecan Liposome Trial of in Advanced Neuroendocrine Carcinoma
Details : Irinotecan HCl is a Other Small Molecule drug candidate, which is currently being evaluated in Phase IV clinical studies for the treatment of Neuroendocrine Tumors.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
June 11, 2025
Details:
Dextromethorphan is a Controlled Substance drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Depressive Disorder, Major.
Lead Product(s): Dextromethorphan,Bupropion Hydrochloride
Therapeutic Area: Psychiatry/Psychology Brand Name: Undisclosed
Study Phase: Phase IIIProduct Type: Controlled Substance
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable May 06, 2025
Lead Product(s) : Dextromethorphan,Bupropion Hydrochloride
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Dextromethorphan is a Controlled Substance drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Depressive Disorder, Major.
Product Name : Undisclosed
Product Type : Controlled Substance
Upfront Cash : Inapplicable
May 06, 2025
Details:
SYHX1901 is a drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Psoriasis.
Lead Product(s): SYHX1901
Therapeutic Area: Dermatology Brand Name: Undisclosed
Study Phase: Phase IIIProduct Type: Undisclosed
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable April 25, 2025
Lead Product(s) : SYHX1901
Therapeutic Area : Dermatology
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
A Phase III Study of SYHX1901 Tablets in the Treatment of Moderate to Severe Plaque Psoriasis
Details : SYHX1901 is a drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Psoriasis.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Inapplicable
April 25, 2025
Details:
Rituximab is a Antibody drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Lymphoma, Large B-Cell, Diffuse.
Lead Product(s): Rituximab,Mitoxantrone,Cyclophosphamide,Vincristine Sulfate,Prednisone
Therapeutic Area: Oncology Brand Name: Undisclosed
Study Phase: Phase IIProduct Type: Antibody, Unconjugated
Sponsor: Xiaohui He
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable April 10, 2025
Lead Product(s) : Rituximab,Mitoxantrone,Cyclophosphamide,Vincristine Sulfate,Prednisone
Therapeutic Area : Oncology
Highest Development Status : Phase II
Partner/Sponsor/Collaborator : Xiaohui He
Deal Size : Inapplicable
Deal Type : Inapplicable
A Study of R-mini-MCOP in the Treatment of Elderly, Previously Untreated DLBCL
Details : Rituximab is a Antibody drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Lymphoma, Large B-Cell, Diffuse.
Product Name : Undisclosed
Product Type : Antibody, Unconjugated
Upfront Cash : Inapplicable
April 10, 2025
Details:
Irinotecan HCl is a Other Small Molecule drug candidate, which is currently being evaluated in clinical studies for the treatment of Rectal Neoplasms.
Lead Product(s): Irinotecan Hydrochloride,Oxaliplatin,Fluorouracil
Therapeutic Area: Oncology Brand Name: Undisclosed
Study Phase: UndisclosedProduct Type: Miscellaneous
Recipient: Peking University Cancer Hospital & Institute
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable March 25, 2025
Lead Product(s) : Irinotecan Hydrochloride,Oxaliplatin,Fluorouracil
Therapeutic Area : Oncology
Highest Development Status : Undisclosed
Recipient : Peking University Cancer Hospital & Institute
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Irinotecan HCl is a Other Small Molecule drug candidate, which is currently being evaluated in clinical studies for the treatment of Rectal Neoplasms.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
March 25, 2025
Details:
Irinotecan is a Other Small Molecule drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Pancreatic Neoplasms.
Lead Product(s): Irinotecan Hydrochloride,Oxaliplatin,Tegafur,Gimeracil,Oteracil
Therapeutic Area: Oncology Brand Name: Undisclosed
Study Phase: Phase IIIProduct Type: Miscellaneous
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable August 26, 2024
Lead Product(s) : Irinotecan Hydrochloride,Oxaliplatin,Tegafur,Gimeracil,Oteracil
Therapeutic Area : Oncology
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Irinotecan is a Other Small Molecule drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Pancreatic Neoplasms.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
August 26, 2024
Details:
SYHX1901 is a drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Alopecia Areata.
Lead Product(s): SYHX1901
Therapeutic Area: Dermatology Brand Name: Undisclosed
Study Phase: Phase IIProduct Type: Undisclosed
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable August 20, 2024
Lead Product(s) : SYHX1901
Therapeutic Area : Dermatology
Highest Development Status : Phase II
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Study to Evaluate Safety and Efficacy of SYHX1901 Tablets in Severe Alopecia Areata Patients
Details : SYHX1901 is a drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Alopecia Areata.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Inapplicable
August 20, 2024
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Inspections and registrations
THIRD-PARTY AUDIT
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]ABOUT THIS PAGE
CSPC Ouyi Pharmaceutical Co., Ltd is a supplier offers 1 products (APIs, Excipients or Intermediates).
Find a price of Indomethacin bulk offered by CSPC Ouyi Pharmaceutical Co., Ltd
